Somaxon announces settlement of Silenor patent litigation with Actavis Somaxon Pharmaceuticals (SOMX) announced that it has entered into a settlement agreement with Actavis Elizabeth and Actavis (ACT) to resolve pending patent litigation involving Silenor 3 mg and 6 mg tablets. The settlement agreement grants Actavis the right to begin selling a generic version of Silenor on January 1, 2020, or earlier under certain circumstances. The settlement agreement will become effective upon the entry by the U.S. District Court for the District of Delaware of an order dismissing the litigation with respect to Actavis.
News For SOMX;ACT From The Last 14 Days
Check below for free stories on SOMX;ACT the last two weeks.